Showing 9 posts of 9 posts found.


Researchers find Achilles’ heel protein in leukaemia

April 26, 2019
Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia

An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …

Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia

November 22, 2018
Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia

Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …


MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016
Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …


Mixed results for new leukaemia drugs

December 9, 2014
Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib

Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …

Daiichi Sankyo image

Daiichi Sankyo pays $410m for Ambit Biosciences

September 29, 2014
Sales and Marketing AML, Daiichi Sankyo, ambit biosciences, quizartinib

Daiichi Sankyo has bought San Diego-based Ambit Biosciences in a deal aimed at shoring up the Japanese company’s cancer research. …

Boehringer targets AML

March 1, 2013
Research and Development, Sales and Marketing AML, Boehringer

Boehringer Ingelheim is to begin a pivotal trial of its investigative treatment volasertib in patients with acute myeloid leukaemia (AML). …

Trial failures threaten UK biotech

February 18, 2011
Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech

A number of late stage failures from British biotech firms have left a looming question mark over the future of …

Pfizer withdraws blood cancer drug in US

June 22, 2010
Sales and Marketing AML, Mylotarg, Pfizer, blood cancer

The US regulatory body has withdrawn Pfizer’s leukaemia drug Mylotarg after it was linked to a number of deaths, and …

Antisoma stages comeback with promising cancer drugs

May 20, 2010
Research and Development AML, Antisoma, chemotherapy, leukaemia

UK biotech Antisoma is looking to put previous late-stage trial failures behind it by focusing on two new cancer drugs. …

Latest content